Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- First Posted Date
- 2004-09-06
- Last Posted Date
- 2012-02-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1228
- Registration Number
- NCT00090753
FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients
Phase 3
Completed
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2004-08-25
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 552
- Registration Number
- NCT00090051
- Locations
- 🇪🇸
Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain
🇺🇸Rush-Presbyterian St. Luke'S Medical Center, Chicago, Illinois, United States
🇨🇦Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada
A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer
- First Posted Date
- 2004-08-06
- Last Posted Date
- 2012-12-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2611
- Registration Number
- NCT00089479
A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients
Phase 2
Completed
- Conditions
- HIV Infections
- Interventions
- Drug: Optimized Background ARVs
- First Posted Date
- 2004-08-06
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 64
- Registration Number
- NCT00089492
REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy
Phase 4
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2004-07-14
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 948
- Registration Number
- NCT00087646
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.
Phase 4
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2004-07-14
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT00087594
Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation
Phase 4
Completed
- Conditions
- Kidney Transplantation
- Interventions
- First Posted Date
- 2004-07-14
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 720
- Registration Number
- NCT00087581
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Phase 4
Terminated
- Conditions
- Breast Cancer
- First Posted Date
- 2004-07-14
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00087620
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin
Phase 4
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2004-07-14
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 57
- Registration Number
- NCT00087568
Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).
Phase 4
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2004-07-14
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 385
- Registration Number
- NCT00087607
© Copyright 2025. All Rights Reserved by MedPath